Send to

Choose Destination
See comment in PubMed Commons below
Gastroenterology. 2010 Oct;139(4):1257-66. doi: 10.1053/j.gastro.2010.06.066. Epub 2010 Jun 27.

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.

Collaborators (149)

Angus P, Bell S, Cheng W, Crawford D, George J, Harley H, Hughes B, Kronborg I, Lee A, Leggett B, Mollison L, Pianko S, Roberts S, Sasadeusz J, Strasser S, Zekry A, Ferenci P, Stauber R, Vogel W, Bailey R, Bain V, Cooper C, Heathcote J, Kaita K, Marotta P, Peltekian K, Sherman M, Swain M, Wong P, Yoshida E, Dlouhy P, Galský J, Husa P, Kumpel P, Plisek S, Rehak V, Urbanek P, Benhamou Y, Bourliere M, Causse X, Couzigou P, Marcellin P, Pawlotsky JM, Poupon R, Trepo C, Berg T, Eisenbach KC, Galle PR, Gerken G, Häussinger D, Manns M, Mauss S, Rasenack JF, Reiser M, Wiegand J, Zeuzem S, Baruch Y, Lurie Y, Safadi R, Shouval D, Tur Kaspar R, Cianciara J, Flisiak R, Gladysz A, Horban A, Jablkowski M, Kryczka W, Mach T, Calistru P, Grigorescu M, Manuc M, Stanciu C, Tanasescu C, Diago M, Esteban Mur R, Forns X, Moreno R, Planas R, Cramp M, Foster G, Main J, Mutimer D, Afdhal N, Arora S, Bacon B, Bennett M, Bernstein D, Brady C, Bzowej N, Carp M, Chasen R, Davis G, Dickson R, Dieterich D, Everson G, Fallon M, Flamm S, Franco J, Fried M, Galati J, Ghalib R, Gibas A, Gitlin N, Godofsky E, Gordon S, Han S, Harrison S, Hassanein T, Herrine S, Herring R, Ho S, Jacobson I, Jeffers L, Joshi S, Kugelmas M, Kwo P, Lambiase L, Lawitz E, Lee W, Lindsay K, Liou I, Lucey M, Monsour H, Nelson D, Nyberg L, Phillips J, Pockros P, Poordad F, Pruitt R, Reau N, Reddy KR, Rodriquez-Torres M, Rubin R, Rustgi V, Schiff E, Schmidt W, Sheikh A, Sheikh M, Sherman K, Shiffman M, Sjogren M, Sulkowski M, Terrault N, Tice A, Tong M, Vargas H, Wiesner R, Wruble L, Younossi Z.



The current standard of care for patients with chronic hepatitis C virus (HCV) genotype 1 is once-weekly pegylated interferon-α (Peg-IFNα) plus daily ribavirin for 48 weeks. We evaluated the efficacy/safety of albinterferon alfa-2b (albIFN), a novel, long-acting, genetic fusion polypeptide of albumin and IFNα-2b.


In the phase 3 ACHIEVE-1 trial, 1331 patients were assigned equally to 3 open-label, 48-week treatment groups: Peg-IFNα-2a 180 μg every week, or albIFN 900 or 1200 μg every 2 weeks administered subcutaneously, with weight-based oral ribavirin 1000-1200 mg/day. During the study, the data monitoring committee recommended dose modification for all patients receiving albIFN 1200 μg to 900 μg because of increased pulmonary adverse events (AEs) in the 1200-μg arms of both ACHIEVE studies. Main outcome measure was sustained virologic response (SVR; undetectable serum HCV RNA at week 72).


Intention-to-treat SVR rates were 51.0% (225/441), 48.2% (213/442), and 47.3% (208/440) with Peg-IFNα-2a, and albIFN 900 and 1200 μg, respectively. The primary objective of showing noninferiority of albIFN 900 μg (P < .001) and 1200 μg (P = .003) vs Peg-IFNα-2a for SVR was achieved. Multivariate modeling indicated consistency of treatment effect across subgroups. Serious/severe AE rates were 23.1%, 24.0%, 28.2%; treatment discontinuation rates because of AEs were 4.1%, 10.4%, 10.0%; discontinuation rates because of respiratory AEs were 0%, 0.9%, 1.6%; with Peg-IFNα-2a, and albIFN 900 and 1200 μg, respectively. Hematologic abnormality rates were comparable across the Peg-IFNα-2a and albIFN 900-μg groups.


albIFN 900 μg every 2 weeks showed comparable efficacy, with similar serious/severe AE rates, although with a higher discontinuation rate, vs Peg-IFNα-2a in patients with chronic HCV genotype 1.


Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Comment in

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk